Consider This: Scientists Question Efficacy And Cost Of Biogen's New Alzheimer's Drug

Biogen’s Aducanumab is the first FDA approved drug intended to treat an underlying cause of Alzheimer’s Disease, but many scientists aren’t convinced that it can actually do that.

The company’s clinical trials of the drug sparked a debate over whether the drug really works, and how much patients should pay for it.

Consider This cohost Arun Rath speaks with WBUR health reporter Angus Chen.